electroCore,

electroCore, Receivables/Revenue

The Receivables to Revenue Ratio of electroCore, (ECOR) as of Oct 17, 2026 is 5.43 %. In the previous year, Receivables to Revenue Ratio was 4.47 % — a change of 21.36% (higher).

Receivables/Revenue

5.43 %

YoY

21.36%

Last updated:

Receivables to Revenue Ratio of electroCore, is 2024 5.43 % . Receivables to Revenue Ratio of electroCore, was 2023 4.47 % . It decreases by 21.36% higher compared to the previous year.

The electroCore, Receivables/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables/Revenue
Date
Receivables/Revenue
Jan 1, 2017
12.32 USD
Jan 1, 2018
27.19 USD
Jan 1, 2019
20.92 USD
Jan 1, 2020
7.72 USD
Jan 1, 2021
8.07 USD
Jan 1, 2022
4.66 USD
Jan 1, 2023
4.47 USD
Jan 1, 2024
5.43 USD
The electroCore, Receivables/Revenue history
YEARReceivables/RevenueYoY
5.43 %+21.36%
4.47 %-3.92%
4.66 %-42.32%
8.07 %+4.51%
7.72 %-63.08%
20.92 %-23.07%
27.19 %+120.65%
12.32 %+56.59%
7.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

electroCore, Stock analysis

What does electroCore, do? electroCore, Inc. is a medical device company based in Basking Ridge, New Jersey, operating in the Health Care sector. The company focuses on non-invasive vagus nerve stimulation (nVNS) therapy, offering a hand-held device called gammaCore. This device provides non-drug treatment for adults experiencing episodic cluster and migraine pain. electroCore's technology targets primary headaches, including migraine and cluster headache, as well as related chronic conditions such as gastric motility disorders, psychiatric issues, sleep disorders, and pain disorders. The company went public via an IPO on June 22, 2018, and currently employs 83 full-time staff. Its headquarters are located in Basking Ridge, and it operates within the Health Care industry. electroCore's primary product, gammaCore, is designed for non-invasive cervical vagus nerve stimulation, aiming to address neurological, psychiatric, gastroenterological, and respiratory conditions. The company's website is https://www.electrocore.com/. electroCore is listed under the ticker ECOR with ISIN US28531P2020. The firm's commercial stage operations emphasize non-invasive therapeutic solutions without pharmaceutical intervention. electroCore, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about electroCore, stock

Receivables to Revenue Ratio of electroCore, is 5.43 % in 2024.

Receivables to Revenue Ratio of electroCore, changed from 4.47 % to 5.43 %, representing a 21.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Receivables to Revenue Ratio electroCore, since 2006 – with annual values, charts, and detailed analysis.

The Receivables/Revenue ratio shows what percentage of annual revenue is tied up in accounts receivable. Rising ratios may signal collection issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Receivables to Revenue Ratio's electroCore, with sector peers and the industry average to assess whether it is attractive.

To evaluate Receivables to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Receivables to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — electroCore,

All Key Metrics — electroCore,